L-Loc Injection contains Terlipressin 1mg, a synthetic vasopressin analogue used primarily for the management of conditions associated with portal hypertension, such as esophageal variceal bleeding and hepatorenal syndrome. Terlipressin acts as a vasoconstrictor by selectively binding to vasopressin V1 receptors on vascular smooth muscle, leading to constriction of splanchnic blood vessels and a consequent reduction in portal venous pressure. This mechanism helps control acute variceal hemorrhage and improves renal perfusion in hepatorenal syndrome by redistributing blood flow. L-Loc Injection is administered intravenously under strict medical supervision, with dosage tailored according to the severity of the condition and patient response. Common adverse effects may include abdominal cramps, hypertension, headache, and peripheral ischemia, necessitating careful monitoring during therapy. Contraindications include ischemic heart disease, peripheral vascular disease, and hypersensitivity to Terlipressin or any excipients. L-Loc Injection should be used with caution in patients with cardiovascular disorders or electrolyte imbalances. It is essential to adhere to recommended dosing regimens and monitor vital signs and laboratory parameters to optimize therapeutic outcomes and minimize potential risks. This product is intended for hospital use and should be handled by healthcare professionals trained in its administration.